FITC/ PE - anti Human CD5/CD19 - L17F12, A3-B1
| Reference | Size | Price | Quantity | Add to cart |
|---|---|---|---|---|
| 5F19PE1-50T | 50 test |
231,00 € tax excl.
|
|
Product Description
- L17F12, A3-B1
- FCM
- FITC/ PE
- Human
- PBS, 0,09% sodium Azide, may contain carrier protein-stabilizer
- RUO
Antigen details
Reactivity & Specifity: CD5 is present on all mature T cells and most thymocytes. It is also expressed on a small subpopulation of normal B cells. The majority of T- cell malignancies (76%) express CD5, and almost 85% of T- cell acute lymphoblastic leukaemias are CD5 positive.
The reactivity of A3-B1 MoAb is directed against the CD19- antigen (B4-antigen), which is expressed on human B lymphocytes. The monoclonal antibody is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells. Plasma cells were found to be negative. The monoclonal antibody does not react with other haemopo?etic cells..
Clinical Application: Further, CD5 is expressed in some B- cell derived lymphoproliferative disorders, notably chronic lymphocytic leukaemia (CLL) (> 90%) (1, 2), and centrocytic leukaemia. CD19 monoclonal antibody also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Virtually all non T-ALL, B-CLL and B-cell lymphomas were found to be positive, myeloma cells were found to be negative. This product can be used for evaluation of residual disease in B-cell chronic lymphocytic leukemia patients and bone-marrow remission.
